Chardan Capital Reaffirms “Buy” Rating for Uniqure (NASDAQ:QURE)

Chardan Capital reaffirmed their buy rating on shares of Uniqure (NASDAQ:QURE) in a research note published on Monday, AnalystRatings.com reports. They currently have a $125.00 price target on the biotechnology company’s stock.

A number of other research firms have also recently commented on QURE. Piper Jaffray Companies reissued a buy rating and set a $80.00 target price on shares of Uniqure in a research report on Tuesday, December 3rd. BidaskClub raised shares of Uniqure from a hold rating to a buy rating in a research report on Thursday, November 28th. Cantor Fitzgerald reissued an overweight rating on shares of Uniqure in a research report on Thursday, October 17th. Goldman Sachs Group started coverage on shares of Uniqure in a research report on Tuesday, December 3rd. They set a buy rating and a $98.00 target price on the stock. Finally, ValuEngine cut shares of Uniqure from a buy rating to a hold rating in a research report on Tuesday, December 3rd. Two research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Uniqure has an average rating of Buy and an average price target of $79.20.

QURE opened at $65.43 on Monday. The company has a quick ratio of 14.33, a current ratio of 14.33 and a debt-to-equity ratio of 0.19. Uniqure has a 52-week low of $24.07 and a 52-week high of $82.49. The company has a 50 day moving average of $54.20 and a two-hundred day moving average of $57.81. The company has a market cap of $2.75 billion, a P/E ratio of -27.96 and a beta of 0.79.

Uniqure (NASDAQ:QURE) last released its quarterly earnings data on Monday, October 28th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.23. Uniqure had a negative net margin of 1,670.86% and a negative return on equity of 51.12%. The company had revenue of $1.05 million during the quarter, compared to the consensus estimate of $2.24 million. Research analysts anticipate that Uniqure will post -2.98 earnings per share for the current year.

In related news, VP Alexander Edward Kuta III sold 4,000 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $47.26, for a total value of $189,040.00. Following the sale, the vice president now directly owns 30,578 shares of the company’s stock, valued at $1,445,116.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Robert Gut sold 4,769 shares of the company’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $47.16, for a total transaction of $224,906.04. Following the completion of the sale, the insider now directly owns 35,378 shares in the company, valued at $1,668,426.48. The disclosure for this sale can be found here. Insiders sold 52,351 shares of company stock worth $2,698,185 over the last ninety days. 2.91% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of QURE. Griffin Asset Management Inc. acquired a new stake in Uniqure in the second quarter valued at $39,000. US Bancorp DE raised its holdings in Uniqure by 275.5% in the second quarter. US Bancorp DE now owns 582 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 427 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new stake in Uniqure in the second quarter valued at $78,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Uniqure by 21.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,975 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 346 shares during the period. Finally, Aperio Group LLC acquired a new stake in shares of Uniqure during the second quarter worth $83,000. 73.13% of the stock is currently owned by hedge funds and other institutional investors.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Featured Story: Using the New Google Finance Tool

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.